PLoS ONE · 2010 · 45 citations · 38 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingHormonal TherapyNuclear ReceptorsProstate CancerSignal Transduction In CancerSteroid Hormone SignalingAdvanced Prostate Cancer TherapyAndrogen Receptor ExpressionAndrogen Receptor RegulationAndrogen ReceptorsBasal Epithelial CellsProstate Cancer Hormonal TherapyProstate CarcinogenesisProstate Growth Regulation
BACKGROUND: Prostate cancer is a common and heterogeneous disease, where androgen receptor (AR) signaling plays a pivotal role in development and progression. The initial treatment for advanced prostate cancer is suppression of androgen signaling. Later on, essentially all patients develop an androgen independent stage which does not respond to anti hormonal treatment. Thus, alternative strategies targeting novel molecular mechanisms are required. beta-TrCP is an E3 ligase that targets various substrates essential for many aspects of tumorigenesis. METHODOLOGY/PRINCIPAL FINDINGS: Here we show that beta-TrCP depletion suppresses prostate cancer and identify a relevant growth control mechanism. shRNA targeted against beta-TrCP reduced prostate cancer cell growth and cooperated with androgen ablation in vitro and in vivo. We found that beta-TrCP inhibition leads to upregulation of the aryl hydrocarbon receptor (AhR) mediating the therapeutic effect. This phenomenon could be ligand independent, as the AhR ligand 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) did not alter prostate cancer cell growth. We detected high AhR expression and activation in basal cells and atrophic epithelial cells of human cancer bearing prostates. AhR expression and activation is also significantly higher in tumor cells compared to benign glandular epithelium. CONCLUSIONS/SIGNIFICANCE: Together these observations suggest that AhR activation may be a cancer counteracting mechanism in the prostate. We maintain that combining beta-TrCP inhibition with androgen ablation could benefit advanced prostate cancer patients.
38
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Tom Dull, Romain Zufferey, Michael T. Kelly et al. · Journal of Virology · 1998 · 3.4K citations · Full text
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen, Derek S. Welsbie, Chris Tran et al. · Nature Medicine · 2003 · 2.3K citations
Medicine, Endocrinology, Urology +17
Identification of the receptor component of the IκBα–ubiquitin ligase
Avraham Yaron, Ada Hatzubai, Matti Davis et al. · Nature · 1998 · 657 citations